QUIZ: AAD Atopic Dermatitis Guidelines

The American Academy of Dermatology (AAD) updated its guidelines to treat atopic dermatitis (AD) last fall.¹ "Guidelines are important to guide treatment decisions but are also important from an insurance coverage standpoint. These updated guidelines validate the clinical decisions that I have been making in clinical practice and give me the confidence to continue to prescribe biologics and JAK inhibitors over traditional systemics and phototherapy. But importantly, from an access standpoint, some insurances require multistep therapy with traditional systemics before approving a biologic or JAK inhibitor for AD. These updated guidelines have the potential to aid clinicians in appealing inappropriate step therapy requirements and can ultimately result in patients gaining access to biologics and JAK inhibitors as first-line therapies for AD,” Mona Shahriari, MD, board-certified dermatologist and assistant clinical professor of dermatology at the Yale University School of Medicine in New Haven, Connecticut, and associate director of clinical trials at Central Connecticut Dermatology Research, told Dermatology Times shortly after the update.²

Ahead of the 2024 AAD Meeting in San Diego, California March 8-12, test your knowledge on the guidelines.

What questions will you ask about the latest guidelines during the 2024 AAD Meeting? We would love to hear from you! Email DTEditor@mmhgroup.com.

References

1. Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol.2023;S0190-9622(23)02878-5. doi:10.1016/j.jaad.2023.08.102

2. Bader K. Expert insights on AAD's updated AD management guidelines for using phototherapy and systemic therapies. Dermatology Times. December 11, 2023. Accessed March 4, 2024. https://www.dermatologytimes.com/view/expert-insights-on-aad-s-updated-ad-management-guidelines-for-using-phototherapy-and-systemic-therapies